SV2017005451A - 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa - Google Patents

1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa

Info

Publication number
SV2017005451A
SV2017005451A SV2017005451A SV2017005451A SV2017005451A SV 2017005451 A SV2017005451 A SV 2017005451A SV 2017005451 A SV2017005451 A SV 2017005451A SV 2017005451 A SV2017005451 A SV 2017005451A SV 2017005451 A SV2017005451 A SV 2017005451A
Authority
SV
El Salvador
Prior art keywords
aminometil
bencil
pirrolo
pyrimidin
tetrahydro
Prior art date
Application number
SV2017005451A
Other languages
English (en)
Inventor
Tord Bertil Inghardt
Nicholas Tomkinson
Li-Ming Gan
Jeffrey Paul Johannesson
Ulrik Jurva
Erik Michaëlsson
Eva-Lotte Lindstedt-Alstermark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SV2017005451A publication Critical patent/SV2017005451A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE DAN A CONOCER DETERMINADOS COMPUESTOS DE 1-[2-(AMINOMETIL)BENCIL]-2-TIOXO-1,2,3,5-TETRAHIDRO-4H-PIRROLO[3,2-D]PIRIMIDIN-4-ONA DE FÓRMULA (I): (VER FORMULA); Y SALES FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, JUNTO CON COMPOSICIONES QUE LOS CONTIENEN Y SU USO EN TERAPIA. LOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA MPC Y DE ESTE MODO SON PARTICULARMENTE ÚTILES EN EL TRATAMIENTO O PROFILAXIS DE TRASTORNOS CARDIOVASCULARES TALES COMO INSUFICIENCIA CARDIACA Y ESTADOS RELACIONADOS CON ARTERIOPATÍA CORONARIA
SV2017005451A 2014-12-01 2017-05-31 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa SV2017005451A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085722P 2014-12-01 2014-12-01
US201562166808P 2015-05-27 2015-05-27

Publications (1)

Publication Number Publication Date
SV2017005451A true SV2017005451A (es) 2017-10-12

Family

ID=54754631

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005451A SV2017005451A (es) 2014-12-01 2017-05-31 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa

Country Status (38)

Country Link
US (4) US9616063B2 (es)
EP (1) EP3227294B1 (es)
JP (1) JP6616417B2 (es)
KR (1) KR102543404B1 (es)
CN (1) CN107001374B (es)
AU (1) AU2015357290B2 (es)
BR (1) BR112017011124B1 (es)
CA (1) CA2968449C (es)
CL (1) CL2017001380A1 (es)
CO (1) CO2017006658A2 (es)
CY (1) CY1122587T1 (es)
DK (1) DK3227294T3 (es)
DO (1) DOP2017000129A (es)
EA (1) EA030805B1 (es)
ES (1) ES2751690T3 (es)
GT (1) GT201700114A (es)
HK (1) HK1245270A1 (es)
HR (1) HRP20191744T1 (es)
HU (1) HUE045606T2 (es)
IL (1) IL252436B (es)
LT (1) LT3227294T (es)
ME (1) ME03568B (es)
MX (1) MX370492B (es)
MY (1) MY195816A (es)
NI (1) NI201700065A (es)
NZ (1) NZ732164A (es)
PE (1) PE20170914A1 (es)
PH (1) PH12017500977A1 (es)
PL (1) PL3227294T3 (es)
PT (1) PT3227294T (es)
RS (1) RS59375B1 (es)
SG (1) SG11201703961UA (es)
SI (1) SI3227294T1 (es)
SV (1) SV2017005451A (es)
TN (1) TN2017000208A1 (es)
TW (1) TWI681963B (es)
UY (1) UY36416A (es)
WO (1) WO2016087338A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
JP7220193B2 (ja) * 2017-07-17 2023-02-09 アストラゼネカ・アクチエボラーグ 医学における使用のためのｍｐｏ阻害剤
CN112151111B (zh) * 2020-08-27 2022-10-11 上海大学 基于多元线性回归快速预测黄嘌呤衍生物抑制活性的qsar方法
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
US20240166642A1 (en) 2022-08-18 2024-05-23 Astrazeneca Ab Inhibitors of myeloperoxidase
US20240092787A1 (en) 2022-08-24 2024-03-21 Astrazeneca Ab Pharmaceutical process and intermediates
WO2024047094A1 (en) 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US20050130983A1 (en) * 2002-05-02 2005-06-16 Dae-Kee Kim Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them
SE0302756D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
GB0401269D0 (en) * 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ATE501148T1 (de) * 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
UY30267A1 (es) 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
JP2009533426A (ja) 2006-04-13 2009-09-17 アストラゼネカ・アクチエボラーグ チオキサンチン誘導体およびそれらのｍｐｏ阻害剤としての用途
WO2007142577A1 (en) 2006-06-05 2007-12-13 Astrazeneca Ab Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
AP2014007621A0 (en) 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
US9616063B2 (en) * 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
US10016430B2 (en) 2018-07-10
CY1122587T1 (el) 2021-01-27
DOP2017000129A (es) 2017-09-15
DK3227294T3 (da) 2019-10-21
TW201639846A (zh) 2016-11-16
MX370492B (es) 2019-12-16
TN2017000208A1 (en) 2018-10-19
IL252436B (en) 2021-05-31
SG11201703961UA (en) 2017-06-29
MX2017007322A (es) 2018-02-19
JP2017535588A (ja) 2017-11-30
AU2015357290B2 (en) 2018-03-29
KR102543404B1 (ko) 2023-06-14
BR112017011124A2 (pt) 2017-12-26
CO2017006658A2 (es) 2017-10-20
WO2016087338A1 (en) 2016-06-09
PT3227294T (pt) 2019-10-28
LT3227294T (lt) 2019-10-25
NI201700065A (es) 2018-01-04
SI3227294T1 (sl) 2019-11-29
BR112017011124B1 (pt) 2022-11-16
KR20170088900A (ko) 2017-08-02
UY36416A (es) 2016-06-01
US11975004B2 (en) 2024-05-07
US11000525B2 (en) 2021-05-11
PH12017500977A1 (en) 2017-11-27
CN107001374A (zh) 2017-08-01
US20190076432A1 (en) 2019-03-14
ES2751690T3 (es) 2020-04-01
EA030805B1 (ru) 2018-09-28
HRP20191744T1 (hr) 2019-12-27
ME03568B (me) 2020-07-20
US9616063B2 (en) 2017-04-11
US20210228585A1 (en) 2021-07-29
TWI681963B (zh) 2020-01-11
HK1245270A1 (zh) 2018-08-24
JP6616417B2 (ja) 2019-12-04
EP3227294A1 (en) 2017-10-11
IL252436A0 (en) 2017-07-31
GT201700114A (es) 2019-08-12
CN107001374B (zh) 2019-06-14
MY195816A (en) 2023-02-22
RS59375B1 (sr) 2019-11-29
NZ732164A (en) 2018-02-23
CA2968449A1 (en) 2016-06-09
PL3227294T3 (pl) 2020-04-30
CA2968449C (en) 2023-02-28
HUE045606T2 (hu) 2020-01-28
EA201791021A1 (ru) 2017-11-30
US20160152623A1 (en) 2016-06-02
PE20170914A1 (es) 2017-07-12
EP3227294B1 (en) 2019-08-14
AU2015357290A1 (en) 2017-06-15
US20170173025A1 (en) 2017-06-22
CL2017001380A1 (es) 2018-01-12

Similar Documents

Publication Publication Date Title
SV2017005451A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
NI201200192A (es) Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica.
BR112014014334A2 (pt) máquina de lavar louça
EA201591743A8 (ru) СТИМУЛЯТОРЫ sGC
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
BR112018012825A2 (pt) derivados de oxadiazol microbiocidas
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
CR20170008A (es) Compuestos de [1,2,4] triazol e imidazol sustituidos
CR20150211A (es) Compuestos diméricos
CO2018004473A2 (es) Compuestos agonistas de ppar y composiciones farmaceuticas
BR112017016488A2 (pt) triazóis substituídos e métodos relacionados aos mesmos
AR101449A1 (es) Inhibidores de myh7b y usos de los mismos
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
WO2016048861A3 (en) Heterocyclic compounds and use thereof
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
BR112018011562A2 (pt) novos derivados de fenil
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.
CO7180196A2 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
CR20170229A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d] pirimidin-4-onas como inhibidores de mieloperoxidasa
CR20170261A (es) Ácido 3-(6-alcoxi-5-clorbenzo[d]isoxazol-3-il)propanoico útil como inhubidores de quinurenina monooxigenasa